Active Stocks
Fri May 24 2024 15:59:27
  1. Tata Steel share price
  2. 174.80 -0.37%
  1. NTPC share price
  2. 374.85 0.68%
  1. State Bank Of India share price
  2. 828.60 -0.45%
  1. ITC share price
  2. 436.10 -1.16%
  1. Power Grid Corporation Of India share price
  2. 318.50 -0.39%
Business News/ Markets / Stock Markets/  US stock markets: Incyte shares climb over 8% on $2 billion stock buyback plan
BackBack

US stock markets: Incyte shares climb over 8% on $2 billion stock buyback plan

At 1:13 p.m. EDT, Incyte Corp shares were at $57.27, 7.93 per cent higher in New York

Last month, Incyte Corp announced that it had entered into a definitive pact to acquire Escient Pharmaceuticals, a clinical-stage company involved in the development of treatment of various skin diseases.Premium
Last month, Incyte Corp announced that it had entered into a definitive pact to acquire Escient Pharmaceuticals, a clinical-stage company involved in the development of treatment of various skin diseases.

Shares of biopharmaceutical company Incyte Corp climbed more than 8 per cent in morning session on Monday after saying it would buy back up to $2 billion of its stock.

At 1:13 p.m. EDT, Incyte Corp shares were at $57.27, 7.93 per cent higher in New York.

Shares Buyback

Incyte on Monday announced that its Board of Directors approved a share repurchase authorization of $2.0 billion.

The company has started a modified “Dutch Auction" tender offer to buy back shares of its common stock for an aggregate purchase price of up to $1.672 billion.

ALSO READ: Wall Street today: US stocks rise as investors eye inflation data

“This tender offer reflects our confidence in the future outlook of our business, the strength of our commercial product portfolio and our clinical development pipeline and Incyte’s long-term value. We believe the current valuation of Incyte stock makes repurchases of our stock an attractive investment and an opportunity to enhance long-term shareholder value," said Hervé Hoppenot, chief executive officer, Incyte Corp.

Quarter Results

On April 30, the Delaware-based company had reported its first quarter profit below Wall Street estimates on weak sales of its blood cancer drug Jakafi.

Jakafi sales fell 1 per cent to $571.8 million in the first quarter.

Its total revenue stood at $880.90 million, below Wall Street estimates. Revenue generated by the drugmaker from royalties was $126 million, up 9 per cent from a year earlier.

Hoppenot had said: “As anticipated, the revenue growth during the quarter was offset by an inventory drawdown for Jakafi and the typical first-quarter net pricing dynamics."

During the first quarter, Incyte had gained worldwide exclusive global rights for Monjuvi, approved by the FDA for the treatment of certain kinds of blood cancer, from MorphoSys AG.

Last month, the drugmaker announced that it had entered into a definitive pact to acquire Escient Pharmaceuticals, a clinical-stage company involved in the development of treatment of various skin diseases. 

You are on Mint! India's #1 news destination (Source: Press Gazette). To learn more about our business coverage and market insights Click Here!

Catch all the Business News, Market News, Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.
More Less
Published: 13 May 2024, 11:04 PM IST
Next Story footLogo
Recommended For You
GENIE RECOMMENDS

Get the best recommendations on Stocks, Mutual Funds and more based on your Risk profile!

Let’s get started